These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 23139017)
1. Case studies for practical food effect assessments across BCS/BDDCS class compounds using in silico, in vitro, and preclinical in vivo data. Heimbach T; Xia B; Lin TH; He H AAPS J; 2013 Jan; 15(1):143-58. PubMed ID: 23139017 [TBL] [Abstract][Full Text] [Related]
2. pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery. Varma MV; Gardner I; Steyn SJ; Nkansah P; Rotter CJ; Whitney-Pickett C; Zhang H; Di L; Cram M; Fenner KS; El-Kattan AF Mol Pharm; 2012 May; 9(5):1199-212. PubMed ID: 22489626 [TBL] [Abstract][Full Text] [Related]
3. The Biopharmaceutics Classification System (BCS) and the Biopharmaceutics Drug Disposition Classification System (BDDCS): Beyond guidelines. Charalabidis A; Sfouni M; Bergström C; Macheras P Int J Pharm; 2019 Jul; 566():264-281. PubMed ID: 31108154 [TBL] [Abstract][Full Text] [Related]
4. Quantitative prediction of formulation-specific food effects and their population variability from in vitro data with the physiologically-based ADAM model: a case study using the BCS/BDDCS Class II drug nifedipine. Patel N; Polak S; Jamei M; Rostami-Hodjegan A; Turner DB Eur J Pharm Sci; 2014 Jun; 57():240-9. PubMed ID: 24060671 [TBL] [Abstract][Full Text] [Related]
5. Prospective Predictions of Human Pharmacokinetics for Eighteen Compounds. Zhang T; Heimbach T; Lin W; Zhang J; He H J Pharm Sci; 2015 Sep; 104(9):2795-806. PubMed ID: 25690565 [TBL] [Abstract][Full Text] [Related]
6. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim. Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464 [TBL] [Abstract][Full Text] [Related]
7. BDDCS Predictions, Self-Correcting Aspects of BDDCS Assignments, BDDCS Assignment Corrections, and Classification for more than 175 Additional Drugs. Hosey CM; Chan R; Benet LZ AAPS J; 2016 Jan; 18(1):251-60. PubMed ID: 26589308 [TBL] [Abstract][Full Text] [Related]
8. In Vitro, in Silico, and in Vivo Assessments of Intestinal Precipitation and Its Impact on Bioavailability of a BCS Class 2 Basic Compound. Kou D; Zhang C; Yiu H; Ng T; Lubach JW; Janson M; Mao C; Durk M; Chinn L; Winter H; Wigman L; Yehl P Mol Pharm; 2018 Apr; 15(4):1607-1617. PubMed ID: 29522347 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of the GastroPlus™ Advanced Compartmental and Transit (ACAT) Model in Early Discovery. Gobeau N; Stringer R; De Buck S; Tuntland T; Faller B Pharm Res; 2016 Sep; 33(9):2126-39. PubMed ID: 27278908 [TBL] [Abstract][Full Text] [Related]
10. Distinguishing between the permeability relationships with absorption and metabolism to improve BCS and BDDCS predictions in early drug discovery. Larregieu CA; Benet LZ Mol Pharm; 2014 Apr; 11(4):1335-44. PubMed ID: 24628254 [TBL] [Abstract][Full Text] [Related]
11. State of the Art and Uses for the Biopharmaceutics Drug Disposition Classification System (BDDCS): New Additions, Revisions, and Citation References. Bocci G; Oprea TI; Benet LZ AAPS J; 2022 Feb; 24(2):37. PubMed ID: 35199251 [TBL] [Abstract][Full Text] [Related]
12. Is the full potential of the biopharmaceutics classification system reached? Bergström CA; Andersson SB; Fagerberg JH; Ragnarsson G; Lindahl A Eur J Pharm Sci; 2014 Jun; 57():224-31. PubMed ID: 24075971 [TBL] [Abstract][Full Text] [Related]
13. BDDCS class prediction for new molecular entities. Broccatelli F; Cruciani G; Benet LZ; Oprea TI Mol Pharm; 2012 Mar; 9(3):570-80. PubMed ID: 22224483 [TBL] [Abstract][Full Text] [Related]
14. A comparative analysis of biopharmaceutics classification system and biopharmaceutics drug disposition classification system: a cross-sectional survey with 500 bioequivalence studies. Cristofoletti R; Chiann C; Dressman JB; Storpirtis S J Pharm Sci; 2013 Sep; 102(9):3136-44. PubMed ID: 23580377 [TBL] [Abstract][Full Text] [Related]
15. Prediction of Biopharmaceutical Drug Disposition Classification System (BDDCS) by Structural Parameters. Golfar Y; Shayanfar A J Pharm Pharm Sci; 2019; 22(1):247-269. PubMed ID: 31287788 [TBL] [Abstract][Full Text] [Related]
16. Provisional classification and in silico study of biopharmaceutical system based on caco-2 cell permeability and dose number. Pham-The H; Garrigues T; Bermejo M; González-Álvarez I; Monteagudo MC; Cabrera-Pérez MÁ Mol Pharm; 2013 Jun; 10(6):2445-61. PubMed ID: 23675957 [TBL] [Abstract][Full Text] [Related]
17. Comparative Oral Drug Classification Systems: Acetazolamide, Azithromycin, Clopidogrel, and Efavirenz Case Studies. Mora MJ; Onnainty R; Granero GE Mol Pharm; 2018 Aug; 15(8):3187-3196. PubMed ID: 29927606 [TBL] [Abstract][Full Text] [Related]
18. The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development. Benet LZ J Pharm Sci; 2013 Jan; 102(1):34-42. PubMed ID: 23147500 [TBL] [Abstract][Full Text] [Related]
19. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Wu CY; Benet LZ Pharm Res; 2005 Jan; 22(1):11-23. PubMed ID: 15771225 [TBL] [Abstract][Full Text] [Related]
20. Forecasting oral absorption across biopharmaceutics classification system classes with physiologically based pharmacokinetic models. Hansmann S; Darwich A; Margolskee A; Aarons L; Dressman J J Pharm Pharmacol; 2016 Dec; 68(12):1501-1515. PubMed ID: 27781273 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]